- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07635108
MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT) (PINPOINT)
Improved MR-Guided Single-fraction Stereotactic Sblative Radiotherapy in Pelvic and Abdominal Nodal Oliorecurrent Prostate Cancer
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
PINPOINT is a prospective, investigator-initiated, single-centre, single-arm phase 2 trial of single-fraction MR-guided SBRT in patients with nodal oligorecurrent prostate cancer. Eligible men have PSMA-PET/CT-verified nodal relapse in the pelvis or abdomen following curatively intended local treatment.
All patients are simulated with MRI in treatment position and treated with 24 Gy in 1 fraction to the gross tumour volume (GTV) using inverse-planned step-and-shoot IMRT on an MR-linac. No CTV margin is added (CTV = GTV); PTV margins account for motion and set-up uncertainty. Normal-tissue constraints are prioritised over target coverage.
The primary endpoint is cumulative CTCAE v5 grade ≥4 treatment-related toxicity within 6 months. Sample size follows a Simon two-stage design (H0: grade 4-5 TRAE rate 15%; H1: 4%; one-sided α = 5%, power 80%), with an interim analysis after 6-month follow-up of the first 16 patients and a total of 48 patients. Follow-up continues for 5 years. Toxicity (CTCAE v5), quality of life (EQ-5D-5L, EORTC QLQ-C30) and patient-reported outcomes (PRO-CTCAE) are collected at baseline and through follow-up; PSA and PSMA-PET/CT (on rising PSA) follow standard of care.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Kristine S Nielsen, MD
- Número de teléfono: +45 31269894
- Correo electrónico: kristine.skovly.nielsen@rsyd.dk
Copia de seguridad de contactos de estudio
- Nombre: Tine Schytte, Professor
- Número de teléfono: +45 21421114
- Correo electrónico: tine-schytte@rsyd.dk
Ubicaciones de estudio
-
-
-
Odense, Dinamarca
- Department of Oncology, Odense University Hospital
-
Contacto:
- Kristine S Nielsen, MD
- Número de teléfono: +45 31269894
- Correo electrónico: kristine.skovly.nielsen@rsyd.dk
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Age ≥ 18 years
- Signed informed consent
- Histologically proven initial diagnosis of adenocarcinoma of the prostate
- ECOG performance status 0-2
- Biochemical recurrence after curatively intended local treatment (radical prostatectomy and/or radiotherapy), with PSMA-PET/CT-verified nodal relapse in the pelvis or abdomen
- Any additional sites of disease beyond the protocol-specified target lymph nodes must be considered suitable for ablative treatment
- Life expectancy > 6 months
- Lymph node size ≤ 2 cm
Exclusion Criteria:
- Medical contraindications to MRI
- Inability to tolerate the physical set-up required for SABR
- Overlap between prior radiation fields and the current target area leading to high risk of clinically significant normal-tissue injury
- Contraindications to pelvic radiotherapy (chronic pelvic inflammatory bowel disease)
- Uncontrolled intercurrent illness
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Single-fraction MR-guided SBRT
All participants receive 24 Gy in a single fraction to the GTV, delivered with MR-guided SBRT.
|
Participants will receive 24 Gy in 1 fraction to a lymph node.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants with cumulative CTCAE v5.0 grade ≥4 treatment-related adverse events
Periodo de tiempo: Within 6 months after completion of radiotherapy
|
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 measures side-effects.
Possible scores range from 0-5, with higher scores indicating a worse outcome.
|
Within 6 months after completion of radiotherapy
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants with late adverse events (CTCAE v5.0)
Periodo de tiempo: 1, 1,5, 2, 3 and 5 years
|
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 measures side-effect. Possible scores range from 0-5, with higher scores indicating a worse outcome. |
1, 1,5, 2, 3 and 5 years
|
|
Percentage of participants free from local progression (PSMA-PET/CT-verified), estimated by time-to-event analysis
Periodo de tiempo: From radiotherapy until local progression or last follow-up, up to 5 years
|
Defined as freedom from PSMA-verified relapse within the treated area.
In the case of significant increase in PSA, a PSMA will be performed as to local guidelines.
Local control will be evaluated at a lesion level, lesion by lesion.
Within the treated area is defined as within or adjacent to the planning target volume (PTV).
|
From radiotherapy until local progression or last follow-up, up to 5 years
|
|
Median clinical progression-free survival
Periodo de tiempo: From radiotherapy up to 5 years
|
Defined as time from inclusion to any new node or distant metastases recurrence.
|
From radiotherapy up to 5 years
|
|
Median time to initiation of palliative ADT (ADT-free survival)
Periodo de tiempo: From inclusion up to 5 years
|
ADT-free survival is defined as the time from trial randomization to start of hormonal treatment
|
From inclusion up to 5 years
|
|
Number of participants with acute adverse events (CTCAE v5.0), by maximum grade
Periodo de tiempo: Within 6 months after radiotherapy
|
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 measures side-effects.
Possible scores range from 0-5, with higher scores indicating a worse outcome.
|
Within 6 months after radiotherapy
|
|
Median overall survival
Periodo de tiempo: From inclusion up to 5 years
|
Overall survival is defined as time form inclusion to death from any cause
|
From inclusion up to 5 years
|
|
Mean change from baseline in EQ-5D-5L index (utility) score
Periodo de tiempo: Baseline, 2 weeks, 3,6 and 12 months
|
The EQ-5D-5L is a standardized, validated generic instrument for health-related quality of life.
It comprises five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with five response levels.
Responses are converted to a single summary index (utility) score using a country-specific (Danish) value set, anchored at 1 = full health and 0 = death, with negative values possible for health states considered worse than death; higher scores indicate better health-related quality of life.
The outcome is reported as the mean change from baseline in the EQ-5D-5L index score at each assessment time point.
|
Baseline, 2 weeks, 3,6 and 12 months
|
|
Mean change from baseline in EORTC QLQ-C30 Global Health Status / QoL scale score
Periodo de tiempo: Baseline, 2 weeks, 3, 6 and 12 months
|
The EORTC QLQ-C30 (version 3.0) is a validated cancer-specific questionnaire for assessing health-related quality of life in clinical trials.
It contains 30 items comprising a global health status / quality of life scale, five functional scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, nausea/vomiting, and pain), and several single-item symptom and financial-impact measures.
Raw scores are linearly transformed to a 0-100 scale according to the EORTC scoring manual; for the global health status / QoL scale a higher score indicates better quality of life.
This outcome is reported as the mean change from baseline in the global health status / QoL scale score at each assessment time point.
|
Baseline, 2 weeks, 3, 6 and 12 months
|
|
Number of participants reporting symptomatic adverse events as assessed by PRO-CTCAE
Periodo de tiempo: Baseline, 2 weeks, 3,6 and 12 months
|
PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events) is a validated patient-reported measurement system developed by the NCI to capture symptomatic toxicity in cancer clinical trials.
A predefined subset of PRO-CTCAE items is used in this trial.
Each symptom is rated by the patient over the prior 7 days across the applicable attributes - frequency (never to almost constantly), severity (none to very severe), and/or interference with usual or daily activities (not at all to very much) - each on a 5-point ordinal scale (scored 0-4).
The outcome is reported as the number of participants in each response category per item and attribute at each assessment time point.
|
Baseline, 2 weeks, 3,6 and 12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Terapia dirigida por metástasis
- PSMA-PET/TC
- Radioterapia corporal estereotáctica
- MR-Linac
- Metástasis en los ganglios linfáticos
- Radioterapia ablativa estereotáctica
- Single-fraction SBRT
- Nodal oligorecurrent prostate cancer
- MR-guided SBRT
- Single-fraction radiotherapy
- Oligometastasis / oligorecurrence
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Procesos Patológicos
- Neoplasias Genitales Masculinas
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades Genitales Masculinas
- Enfermedades prostáticas
- Enfermedades urogenitales masculinas
- Procesos Neoplásicos
- Metástasis de neoplasias
- Condiciones Patológicas, Signos y Síntomas
- Neoplasias prostáticas
- Metástasis linfática
Otros números de identificación del estudio
- OP-2499
- S-20250058 (Otro identificador: Ethics committee)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .